VeGen Labs LLP
VeGen Labs LLP is a pre-revenue, founder-controlled Indian precision oncology company developing targeted therapeutics for metastatic solid tumors (NSCLC, colorectal, pancreatic) using computational chemistry, AI-assisted lead identification, and proprietary drug delivery platforms, with the goal of affordable pricing in Asian markets.
- Company typePrivate
- Founded-
- HeadquartersHyderabad, India
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What VeGen Labs LLP does
VeGen Labs LLP is a pre-revenue, founder-controlled precision oncology company registered as a Limited Liability Partnership in India, with headquarters at the ASPIRE bioincubator within the University of Hyderabad's School of Life Sciences (Gachibowli, Hyderabad) and a secondary site at the BSC BioNest Bioincubator in Faridabad, Haryana. The company is developing a pipeline of targeted therapeutics against cancer signaling pathways in metastatic solid tumors, with an explicit focus on non-small cell lung cancer, colorectal cancer, and pancreatic cancer, designed for use both as single agents and in combination with chemotherapy, immunotherapy, and other targeted agents.
The underlying technology stack combines computational chemistry and computer-aided drug design (CADD) for AI-assisted lead identification and optimization with a set of proprietary drug delivery platforms: a Solid Core Drug Delivery System (SCDDS) for oral delivery of biomolecules, supercritical CO2 processing for solubility enhancement and solvent-free coating, and non-aqueous nasal delivery formulations including nose-to-brain transport of nucleic acid-based drugs. A four-member Scientific Advisory Board provides scientific oversight across oncology, drug delivery, medicinal chemistry, and AI-driven precision medicine.
VeGen's business model is built around cost-efficient drug development intended to enable affordable pricing in India and other Asian markets where Western-origin precision oncology treatments remain inaccessible due to limited insurance coverage. The company explicitly minimizes reliance on large sales forces and advertising budgets and operates through partnerships across the drug development and healthcare spectrum rather than a traditional commercial sales motion. As of the available data, the company is pre-revenue, has no disclosed funding rounds or institutional investors, and is supported by a 6-person operating team.
VeGen Labs LLP firmographics
Firmographics- Name
- VeGen Labs LLP
- Legal name
- VeGen Labs LLP
- Website
- https://vegen.in
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- VeGen Labs LLP is a pre-revenue, founder-controlled Indian precision oncology company developing targeted therapeutics for metastatic solid tumors (NSCLC, colorectal, pancreatic) using computational chemistry, AI-assisted lead identification, and proprietary drug delivery platforms, with the goal of affordable pricing in Asian markets.
- Ownership category
- akta.pro rank
VeGen Labs LLP industry classification
Industry- Product category
- Precision Oncology Drug Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Oncology & Hematology Pharmaceuticals (HLAIAAAC), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where VeGen Labs LLP is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
VeGen Labs LLP business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development and Commercialization: Pre-revenue biotech company focused on developing precision oncology therapeutics through clinical development stages. Revenue model based on eventual pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Marketing channels2 records
VeGen Labs LLP product offering
Product offeringCore offering
VeGen Labs LLP is a precision oncology drug discovery and development company that builds a pipeline of targeted therapeutics for metastatic solid tumors. Its focus indications are non-small cell lung cancer, colorectal cancer, and pancreatic cancer, with drug candidates intended for use both as single agents and in combination with chemotherapy, immunotherapy, and other targeted agents. The company pairs novel medicinal chemistry and computer-aided drug design with proprietary drug delivery platforms (oral biomolecule delivery, nasal/nose-to-brain delivery, supercritical CO2 processing) to develop affordable cancer medicines for patients in India and Asia.
Product overview
VeGen Labs LLP is a precision oncology company operating as a single unified drug discovery and development platform. The company develops targeted cancer therapeutics targeting pathways in metastatic solid tumors, with a focus on non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Their approach combines novel drug candidates designed to work both as single agents and in combination with existing treatment regimens including chemotherapy, immunotherapy, and targeted agents. The company aims to bring affordable cancer treatments to patients in India and Asia by minimizing development costs and reducing reliance on extensive sales and advertising budgets.
Differentiator
Problem solved
Functional benefit
Products and services
- Precision Oncology Drug Pipeline A precision oncology drug development pipeline targeting cancer signaling pathways in metastatic solid tumors, with active focus on non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Designed for use as a single agent and in combination with chemotherapy, immunotherapy, and other targeted agents. Currently in pre-revenue discovery/development; intended end users are cancer patients (especially in India and Asia) with high unmet medical need.
Companies that use VeGen Labs LLP
Customer profileSegments4 records
Ideal customer profiles2 records
VeGen Labs LLP technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
VeGen Labs LLP partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- UoH (University of Hyderabad)coreVeGen is located at ASPIRE, School of Life Sciences at University of Hyderabad, indicating a strategic partnership for research and development activities.
- BSC BioNest BioincubatorcoreRegional Centre for Biotechnology bioincubator facility supporting biotech startups and research; VeGen has a facility location at this bioincubator in Faridabad.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
VeGen Labs LLP competitors and assessment
Company assessmentRegional players
- Syngene International: India-headquartered integrated CRO offering discovery, development, and manufacturing services with strong oncology small-molecule capabilities. Comparable as an India-based scientific services platform serving global pharma R&D.
- Sai Life Sciences: India-based integrated CRO/CDMO offering drug discovery services including CADD, medicinal chemistry, and DMPK. Comparable as an Indian-headquartered partner providing discovery services to global pharma, with overlapping CADD and medicinal chemistry capabilities.
Direct peers
- Suven Pharma: India-based pharma with CNS and oncology programs; founder Prashant Bhavar's prior institution. Closely comparable in therapeutic focus and Indian operational base, with shared scientific lineage through the SUVN-502 program.
- Blueprint Medicines: Precision therapy company developing kinase-targeted small molecules for cancer and rare diseases. Comparable in approach as a precision oncology innovator targeting cancer signaling pathways with combination-therapy potential.
- Advinus Therapeutics: India-based drug discovery and development company with oncology and metabolic disease focus. Comparable in scale and stage as an early-stage Indian innovator pharma pursuing novel small molecules from Indian research infrastructure.
- Mirati Therapeutics: Precision oncology company targeting genetically defined cancer drivers (e.g., KRAS G12C). Comparable as a small-molecule precision oncology innovator focused on cancer signaling pathways, though at more advanced clinical stage.
- Aurigene Discovery Technologies: India-based precision oncology and inflammation drug discovery company offering both standalone programs and CRO services. Directly comparable as an Indian-headquartered small-molecule oncology discovery platform with CADD capabilities and combination-therapy focus.
Broad incumbents
- NATCO Pharma: Larger Indian pharma with significant oncology franchise focused on affordable generic and novel oncology products. Comparable as an Indian-headquartered company pursuing affordable oncology treatments for emerging markets, though at much greater scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
VeGen Labs LLP social profiles
Digital presenceVeGen Labs LLP financial estimates
Financial estimateRevenue estimate
Valuation estimate
VeGen Labs LLP leadership team
Management profileNumber of profiles
Profiles7 records
VeGen Labs LLP funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VeGen Labs LLP M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VeGen Labs LLP
What does VeGen Labs LLP do?
VeGen Labs LLP is a precision oncology drug discovery and development company that builds a pipeline of targeted therapeutics for metastatic solid tumors. Its focus indications are non-small cell lung cancer, colorectal cancer, and pancreatic cancer, with drug candidates intended for use both as single agents and in combination with chemotherapy, immunotherapy, and other targeted agents. The company pairs novel medicinal chemistry and computer-aided drug design with proprietary drug delivery platforms (oral biomolecule delivery, nasal/nose-to-brain delivery, supercritical CO2 processing) to develop affordable cancer medicines for patients in India and Asia.
Is VeGen Labs LLP a public or private company?
VeGen Labs LLP is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was VeGen Labs LLP founded?
VeGen Labs LLP was founded in -1. It employs 1 to 10 people.
Where is VeGen Labs LLP based?
VeGen Labs LLP is headquartered in Hyderabad, India, in the Asia region.
How does VeGen Labs LLP make money?
One revenue line is on record: drug Development and Commercialization.
Who are VeGen Labs LLP's main competitors?
Regional players on record are Syngene International and Sai Life Sciences. Direct peers are Suven Pharma, Blueprint Medicines, Advinus Therapeutics, Mirati Therapeutics and Aurigene Discovery Technologies. NATCO Pharma is listed as a broad incumbent.
Does VeGen Labs LLP have an API?
No public API is recorded for VeGen Labs LLP.
What industry is VeGen Labs LLP in?
VeGen Labs LLP's product category is Precision Oncology Drug Development. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.